Most weight lost with GLP-1-based treatment appears to come from fat, and modest reductions in muscle size do not automatically cause declining strength or function
95% confidence interval, 10.0 to 6.3 mmol mol 1 ), with a pronounced effect in those with SIDD
How It Works Semaglutide acts on GLP-1 receptors in the pancreas, brain, and gut to: Stimulate insulin release only when glucose levels are high Suppress glucagon secretion, lowering hepatic glucose output Slow gastric emptying to reduce post-meal glucose spikes Decrease appetite and promote satiety Although the 3 mg dose has limited metabolic impact, it activates these pathways at a low level to reduce side effects as the dose increases
Es, en esencia, el hermano de Ozempic
More energy means more movement
Staying hydrated, maintaining fiber intake, and following our nutrition guidance keeps this manageable for most patients